DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative
Casgevy, the world's first approved CRISPR-based cell therapy, has been priced at $2.2 million per patient. Although this hefty price tag was widely anticipated, the extremely high cost of this and other cell and gene therapies poses a major ethical issue in terms of equitable access and global health. In this Perspective, we argue that lowering the prices of future CRISPR therapies is an urgent ethical imperative. Although we focus on Casgevy as a case study, much of our analysis can be extrapolated to the controversies over affordable access to other gene and cell therapies. First, we explain why this first-of-its-kind CRISPR therapy might be so expensive. We then analyze the ethical issues of equity and global health of early CRISPR treatments. Next, we discuss potential solutions to lower the prices of CRISPR gene therapies. We conclude that the approval of CRISPR transforms our obligations of justice and compels us to bring future gene therapies to the maximum possible number of patients with serious genetic diseases at affordable prices., J.R. thanks funding from a U.S.-Spain Fulbright grant, an INPhINIT Retaining Fellowship of the La Caixa
Foundation (Grant number LCF/BQ/DR20/11790005), Conselho Nacional de Desenvolvimento Cientíco e Tecnológico (421523/2022-0 and 421419/2023-7) and the Sabadell Foundation. IDM acknowledges the support of the Basque Government, Ayudas a grupos de
investigación, Grupo de Investigación IT 1541-22, and research project GODAS, PID2022-137140OB-I00, funded by MCIN/AEI/10.13039/501100011033/FEDER,UE. LM acknowledges the support of the Spanish Ministry of Science and Innovation under PID2021-127644OB-I00, CIBERER and Fundación Ramón Areces., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-137140OB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2021-127644OB-I00
DOI: http://hdl.handle.net/10261/373517, https://api.elsevier.com/content/abstract/scopus_id/85207622030
HANDLE: http://hdl.handle.net/10261/373517, https://api.elsevier.com/content/abstract/scopus_id/85207622030